NCT02099058 (Clinical Trial/ ABBV-399)

Study Title
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors (NCT02099058)

Trial Description
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in subjects with advanced solid tumors.

This trial is sponsored by AbbVie®.

Study Data

  • Condition: 
    • Advanced Solid Tumor Cancer
  • Interventions:
    • Drugs used in this trial
      • ABBV-399
      • Erlotinib
      • Cetuximab
      • Bevacizumab
      • Nivolumab
  • Phase: I
  • Estimated Enrollment: 146
  • Start: April 2014
  • Estimated Completion: April 2017
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: April 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.